跳至主要内容
临床试验/JPRN-jRCT1041190098
JPRN-jRCT1041190098招募中未知

A multicenter pre- and post-comparison study regarding the effect of pemafibrate in improving liver fibrosis in nonalcoholic fatty liver disease with dyslipidemia

Kawata Kazuhito0 个研究点目标入组 20 人开始时间: 2019年12月17日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1. Twenty years old or more
  • 2. Detected fatty liver by imaging (e.g. ultrasonography, composed tomography, magnetic resonance imaging)
  • 3. Serum ALT > 31 U/L
  • 4. Fasting serum triglyceride > 150 mg/dL or serum high-density lipoprotein cholesterol < 40 mg/dL
  • 5. Written informed consent was obtained from the patient

排除标准

  • 1. Alcohol habitual consumption
  • 2. Anti-HCV positive or HBs-antigen positive
  • 3. Autoimmune hepatitis or primary biliary cholangitis
  • 4. Wilson's disease or hemochromatosis
  • 5. Past history of coronary disease
  • 6. Hyperlipidemia (triglyceride > 500 mg/dL)
  • 7. Uncontrollable plasma glucose
  • 8. Cirrhosis
  • 9. Biliary obstruction
  • 10. Moderate or severe renal function disorder
  • 11. Galle stone
  • 12. Familial hyperlipidemia
  • 13. Corticosteroid or anti-estrogen
  • 14. Cyclosporin or rifampicin
  • 15. Allergy for pemafibrate
  • 16. Expecting mother
  • 17. Considered as inadequacy for this research

研究者

发起方
Kawata Kazuhito

相似试验